{"id":987500848,"date":"2021-08-06T12:32:37","date_gmt":"2021-08-06T12:32:37","guid":{"rendered":"https:\/\/boracdmo.com\/kyowa-pharmaceutical-industry-co-ltd-partners-with-bora-pharmaceuticals-to-manufacture-generic-product-for-filing-in-japan-2\/?lang=en"},"modified":"2025-07-25T13:14:48","modified_gmt":"2025-07-25T13:14:48","slug":"kyowa-pharmaceutical-industry-co-ltd-partners-with-bora-pharmaceuticals-to-manufacture-generic-product-for-filing-in-japan-2","status":"publish","type":"post","link":"https:\/\/boracdmo.com\/kyowa-pharmaceutical-industry-co-ltd-partners-with-bora-pharmaceuticals-to-manufacture-generic-product-for-filing-in-japan-2\/","title":{"rendered":"KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to manufacture generic product for filing in Japan"},"content":{"rendered":"<p>KYOWA Pharmaceutical Industry Co. Ltd., a premier Japanese pharmaceutical company, has contracted with Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals for the manufacturing of generic product for filing in Japan. KYOWA will be the first Japanese client for Bora\u2019s Zhunan manufacturing site which is already USFDA, MHRA, and TFDA approved.<\/p>\n<p>This project will coordinate the manufacturing strengths in Taiwan and increase the visibility of Taiwan\u2019s pharmaceutical capabilities. It further demonstrates the cooperation between Japan\u2019s and Taiwan\u2019s pharmaceutical companies.<\/p>\n<p>The manufactured batches will be used to further support Bioequivalence (BE) studies and then submitted to Japan\u2019s PMDA for approval. Upon PMDA\u2019s approval, Bora will be the commercial manufacturing site for the generic product production. Bora Pharmaceuticals\u2019 sites already have an excellent track record with many regulatory agencies around the world including the USFDA, MHRA, TFDA, ANVISA, Health Canada, and many others.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>KYOWA Pharmaceutical Industry Co. Ltd., a premier Japanese pharmaceutical company, has contracted with Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals for the manufacturing of generic product for filing in Japan. KYOWA will be the first Japanese client for Bora\u2019s Zhunan manufacturing site which is already USFDA, MHRA, and TFDA approved. This project [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":987500850,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[58],"tags":[],"class_list":["post-987500848","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"aioseo_notices":[],"acf":[],"_links":{"self":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts\/987500848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/comments?post=987500848"}],"version-history":[{"count":0,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts\/987500848\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/media\/987500850"}],"wp:attachment":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/media?parent=987500848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/categories?post=987500848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/tags?post=987500848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}